申请人:TOYAMA CHEMICAL CO., LTD.
公开号:EP1820795A1
公开(公告)日:2007-08-22
An anthranilic acid derivative represented by the general formula (X) [wherein R1 represents hydrogen or a carboxy-protecting group; R2 represents optionally substituted phenyl, a heterocyclic group, etc.; R3 represents optionally substituted phenyl, a monocyclic heterocyclic group, etc.; X1 represents carbonyl, etc.; X2 represents optionally substituted alkylene group, a bond, etc.; X3 represents oxygen, a bond, etc.; and X4 represents a group represented by the general formula -X5-X6- or -X6-X5- (wherein X5 means oxygen, a bond, etc.; and X6 means optionally substituted alkylene, a bond, etc.)] or a salt of the derivative. The derivative or salt has the inhibitory activity of MMP-13 production and is hence useful as a therapeutic agent for articular rheumatism, osteoarthritis, cancer, etc.
通式(X)代表的蒽酸衍生物[其中 R1 代表氢或羧基保护基团;R2 代表任选取代的苯基、杂环基团等;R3 代表任选取代的苯基、单环杂环基团等;X1 代表羰基等;X2 代表任选取代的亚烷基、键等;X3 代表氧、键等;X4 代表通式 -X5-X6- 或 -X6- 所代表的基团。X2 代表任选取代的亚烷基、键等;X3 代表氧、键等;X4 代表通式 -X5-X6- 或 -X6-X5- 所代表的基团(其中 X5 代表氧、键等;X6 代表任选取代的亚烷基、键等)]或衍生物的盐。衍生物或盐具有抑制 MMP-13 生成的活性,因此可用作关节风湿病、骨关节炎、癌症等的治疗剂。